RCOR3

REST corepressor 3 · Q9P2K3 · RCOR3 on Sugi Atlas →

3,442 patent compounds predicted against RCOR3, 2,777 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Vorinostat (SCHEMBL9018)	1.00	1/20
(+)-Tranylcypromine (SCHEMBL34339)	1.00	1/20
(+)-Tranylcypromine (SCHEMBL40651)	1.00	1/20
(+)-Tranylcypromine (SCHEMBL145650)	1.00	1/20
(+)-Tranylcypromine (SCHEMBL1649712)	1.00	1/20
(+)-Tranylcypromine (SCHEMBL1720497)	1.00	1/20
(+)-Tranylcypromine (SCHEMBL2755938)	1.00	1/20
(+)-Tranylcypromine (SCHEMBL3406205)	1.00	1/20
(+)-Tranylcypromine (SCHEMBL56350)	0.95	1/20
(+)-Tranylcypromine (SCHEMBL56351)	0.95	1/20
(+)-Tranylcypromine (SCHEMBL56352)	0.95	1/20
(+)-Tranylcypromine (SCHEMBL145687)	0.95	1/20
(+)-Tranylcypromine (SCHEMBL4380284)	0.95	1/20
SCHEMBL137348	0.85	1/20
SCHEMBL1065393	0.85	1/20
SCHEMBL517309	0.81	1/20
Hydroxyamine (SCHEMBL1268824)	0.79	1/20
SCHEMBL312344	0.77	1/20
SCHEMBL1064861	0.77	1/20
(+)-Tranylcypromine (SCHEMBL40650)	0.75	1/20

Clinical trials — most relevant to RCOR3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer	PHASE2	UNKNOWN
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS	PHASE2	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)	PHASE1/PHASE2	COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Decitabine in Treating Patients With Myelofibrosis	PHASE2	ACTIVE_NOT_RECRUITING
10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1	PHASE2	COMPLETED
Safety and Pharmacokinetic Profile of CKD-581	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
A Study of Multilocus Methylation Abnormalities in Subjects With Imprinting Disorders	nan	NOT_YET_RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Thermogenic Silencer Regulatory Factors in Humans	nan	ACTIVE_NOT_RECRUITING
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581	nan	COMPLETED
Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women	nan	COMPLETED
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors	nan	UNKNOWN
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Evaluation of the Predictive Effect of Inflammatory Markers in MI Patients	nan	UNKNOWN
Gene Expression Variation and Implant Wound Healing Among Smokers and Diabetics	nan	COMPLETED
Family Resilience Initiative Research Program	nan	UNKNOWN
The PRE-OP ENERGY Trial	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a RCOR3 binder may also engage these)

Protein	Name	Similarity
Q6P116	—	1.000	Q6P116 →
Q6PGA0	—	0.998	Q6PGA0 →
Q6NRZ0	—	0.996	Q6NRZ0 →
RCOR1	REST corepressor 1 (Protein CoREST)	0.996	landscape →
Q8CFE3	—	0.995	Q8CFE3 →
Q5FWT8	—	0.990	Q5FWT8 →
P97496	—	0.990	P97496 →
SMARCC1	SWI/SNF complex subunit SMARCC1	0.990	landscape →
Q8C796	—	0.989	Q8C796 →
SMARCC2	SWI/SNF complex subunit SMARCC2	0.989	landscape →
A1Z7T0	—	0.988	A1Z7T0 →
Q8TC92	—	0.988	Q8TC92 →
O43439	—	0.988	O43439 →
Q17QQ4	—	0.988	Q17QQ4 →
Q90WN5	—	0.988	Q90WN5 →
Q32NW2	—	0.987	Q32NW2 →
Q8BHR2	—	0.987	Q8BHR2 →
Q9JHD2	—	0.987	Q9JHD2 →
Q6PDG5	—	0.986	Q6PDG5 →
Q80U87	—	0.986	Q80U87 →
Q8BX57	—	0.986	Q8BX57 →
Q8IZ40	—	0.986	Q8IZ40 →
Q91857	—	0.986	Q91857 →
Q4R4J1	—	0.986	Q4R4J1 →
Q5RAY5	—	0.986	Q5RAY5 →
NFRKB	Nuclear factor related to kappa-B-binding protein	0.986	landscape →
Q2T9I5	—	0.985	Q2T9I5 →
Q28E45	—	0.985	Q28E45 →
Q4V7D7	—	0.985	Q4V7D7 →
TAF9	Transcription initiation factor TFIID subunit 9	0.985	landscape →